Please provide your email address to receive an email when new articles are posted on . Sacubitril/valsartan showed benefit across the spectrum of left ventricular ejection fraction in stable patients ...

Data from an open-label, fixed-sequence study showed that although sacubitril inhibited organic anion-transporting polypeptides (OATP)1B1 and OATP1B3 in vitro, this did not translate to any clinically ...

Individuals with a history of acute myocardial infarction (AMI), or heart attack, may benefit on several fronts following early administration of the neprilysin inhibitor/angiotensin receptor blocker ...

Treatment with sacubitril/valsartan, a pillar of therapy for patients with chronic heart failure with below-normal ejection fraction, came suggestively close to showing efficacy for preventing ...

Sacubitril/valsartan does not change cognitive function, compared with valsartan, in patients with heart failure and mildly reduced or preserved ejection fraction, according to late breaking research ...

The cost avoidance of heart failure–related hospitalizations and emergency department visits may outweigh the additional drug cost in Medicaid members adherent to sacubitril/valsartan. Objective: To ...

Please provide your email address to receive an email when new articles are posted on . “We were surprised and disappointed, and stared at the data for a long time, partly in disbelief,” Mann, who is ...

The FDA has accepted for review the supplemental New Drug Application (sNDA) for sacubitril/valsartan (Entresto; Novartis) in the treatment of heart failure with preserved ejection fraction. The Food ...

Sacubitril/valsartan may be a better treatment option compared with ACEi/ARBs for patients with malignant hypertension-associated thrombotic microangiopathy. Kidney recovery is better when thrombotic ...

Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone after stabilization for worsening heart failure in patients with an ejection fraction (EF) above ...